NewcelX Ltd.
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
NewcelX Ltd. (NCEL) - Total Liabilities
Latest total liabilities as of September 2025: $1.46 Million USD
Based on the latest financial reports, NewcelX Ltd. (NCEL) has total liabilities worth $1.46 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NewcelX Ltd. - Total Liabilities Trend (2017–2024)
This chart illustrates how NewcelX Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NewcelX Ltd. Competitors by Total Liabilities
The table below lists competitors of NewcelX Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RedFlow Limited
PINK:REFXF
|
USA | $4.79 Million |
|
SKELLERUP HLDGS
BE:RZK
|
Germany | €117.54 Million |
|
LEIFRAS Co., Ltd. American Depositary Shares
NASDAQ:LFS
|
USA | $3.48 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down NewcelX Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NewcelX Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NewcelX Ltd. (2017–2024)
The table below shows the annual total liabilities of NewcelX Ltd. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $826.76K | -92.26% |
| 2023-12-31 | $10.68 Million | +78.13% |
| 2022-12-31 | $6.00 Million | +14.81% |
| 2021-12-31 | $5.22 Million | -48.78% |
| 2020-12-31 | $10.20 Million | +48.46% |
| 2019-12-31 | $6.87 Million | -23.35% |
| 2018-12-31 | $8.96 Million | -10.46% |
| 2017-12-31 | $10.01 Million | -- |